



---

Food and Drug Administration  
Rockville, MD 20857

July 23, 2004

David M. Fox  
Hogan & Hartson  
555 Thirteenth Street N.W  
Washington, DC 20004

Dear Mr. Fox:

Your petition, on behalf of Abbott Laboratories, requesting the Food and Drug Administration to reconsider its June 23, 2004 decision denying a request to establish a clinically sensitive and scientifically valid bioequivalence (BE) methodology for oral levothyroxine sodium drug products, was received by this office on 07/23/2004. It was assigned docket number 2003P-0387/PRC1 and it was filed on 07/23/2004. Please refer to this docket number in future correspondence on this subject with the Agency.

Please note that the acceptance of the petition for filing is a procedural matter in that it in no way reflects an agency decision on the substantive merits of the petition.

Sincerely,

Jennie C. Butler, Director  
Division of Dockets Management  
Office of Management Programs  
Office of Management